Advertisement
Nonclinical research data by Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) on the immunologic mechanism of action of PV-10 confirms that PV-10 chemoablation of melanoma lesions leads to a systemic response and the induction of systemic anti-tumor immunity. At the annual meeting of the Society of Surgical Oncology, presenter Paul Toomey, MD confirmed that intratumoral PV-10 causes both a direct anti-tumoral response of the injected tumor and a systemic tumor-specific activation of the immune system.
Click here for more industry news and clinical trial updates.
Advertisement
TOP 5 ARTICLES FROM 2012
- Understanding the Role of Natural Moisturizing Factor in Skin Hydration
Components collectively called natural moisturizing factor (NMF) that occur naturally in the skin can be delivered topically to treat xerotic, dry skin.
By Joseph Fowler, MD, FAAD
- MiraDry: A Notable Advance in Treating Primary Axillary Hyperhidrosis
Harnessing the power of microwaves, a new device offers a patient-friendly option for the treatment of hyperhidrosis.
By William P. Coleman, III, MD, W. Patrick Coleman IV, MD, and Kyle M. Coleman, MD
- The PA Salary: Structures and Strategies
Just as there is a wide range of practice settings that utilize a PA, there is an array of salary structures for PAs. Choose a structure that is fair and mutually beneficial.
By Katherine Wilkens, PA-C, MHIS, MPAP
- Make the Most of Cosmeceutical Agents in Your Practice
Experts weigh in on the science of cosmeceuticals and provide recommendations on specific agents.
By Joel Schlessinger, MD
- Rosacea Therapy:
Current Approaches
and Future Directions
New topical formulations in development may become the first treatments approved for the reduction of erythema associated with rosacea.
By Joseph Bikowski, MD
Sides Media.